New article published in JAMA discusses on the current state of breast cancer screening in the United States.
WHO: Nancy L Keating, MD, MPH, primary care physician, Division of General Internal Medicine, Brigham and Women's Hospital; professor, Harvard Medical School
Lydia E. Pace, MD, MPH, primary care physician, Division of Women's Health and General Internal Medicine; Director of the Women's Health Policy and Advocacy Program, Connors Center for Women's Health, BWH; assistant professor, HMS
Better Than Mammograms: A Pill to Diagnose Breast Cancer Accurately
A pill that makes tumors light up when exposed to infrared light could make breast cancer diagnosis more precise than using a mammogram and has been tested in a mice study.
Advertisement
‘Consider the risk and engage in shared decision-making about breast cancer screening, authors recommend.’
Tweet it Now
WHAT: The authors note, that despite the fact that the United States Preventive Services Task Force (USPSTF) changed its recommendation of breast cancer screening in 2009 to mammograms every two years for women aged 50-74 instead of annual mammograms beginning at age 40, there has been little change in U.S. screening practices. They further point out that the USPSTF reiterated its recommendation in 2016 and that the American Cancer Society joined the task force in 2015 in advocating less routine use of mammography and a more individualized approach to screening.
In the Insights article, Keating and Pace highlight potential reasons for the limited change in mammography practices, such as clinicians emphasizing the benefits of screening without discussing the possible harms. "However, the most important contributor to limited uptake of these guidelines may be the challenge clinicians have in truly engaging patients in shared decision-making to individualize screening decisions," the authors write.
![Carboplatin Benefits Women With Aggressive Breast Cancer]( "Carboplatin Benefits Women With Aggressive Breast Cancer")
Targeting chemotherapy with genetic testing benefits women with aggressive breast cancer, revealed scientists.
The authors point out that although mammography screening has been shown to lower breast cancer death risk, the number of deaths prevented is very small.
"One of the greatest harms is over-diagnosis, which can subject some women to harmful treatment without any benefit," Pace said. "Additionally, high rates of false positives and unnecessary biopsies should be considered as likely outcomes of breast cancer screening."
The authors also raise concerns about current quality measures that assess the proportion of women who have had a mammogram in the past two years. They argue that "...given the modest benefits of mammography screening and real harms across all age groups, a more appropriate measure for accountability would be whether physicians assessed patients' risk of breast cancer and engaged patients in shared decisions about when and how often to undergo mammography screening.
"All patients should participate in shared discussions with their clinicians about mammography that consider their risk of cancer, summarize the benefits and harms of screening, and take into account patient values and preferences," Keating said.
The authors conclude that until new and better screening tests provide more benefit and fewer harms for patients, more efforts are needed to develop tools to support clinicians and patients in determining individual breast cancer risk and in making shared decisions about mammography.
In a supplement to the JAMA Insights article, the authors provide currently available resources to support shared decisions about breast cancer screening, including an animated video available here.
Source: Eurekalert
Carboplatin Benefits Women With Aggressive Breast Cancer
Targeting chemotherapy with genetic testing benefits women with aggressive breast cancer, revealed scientists.
Advertisement
The authors point out that although mammography screening has been shown to lower breast cancer death risk, the number of deaths prevented is very small.
"One of the greatest harms is over-diagnosis, which can subject some women to harmful treatment without any benefit," Pace said. "Additionally, high rates of false positives and unnecessary biopsies should be considered as likely outcomes of breast cancer screening."
The authors also raise concerns about current quality measures that assess the proportion of women who have had a mammogram in the past two years. They argue that "...given the modest benefits of mammography screening and real harms across all age groups, a more appropriate measure for accountability would be whether physicians assessed patients' risk of breast cancer and engaged patients in shared decisions about when and how often to undergo mammography screening.
"All patients should participate in shared discussions with their clinicians about mammography that consider their risk of cancer, summarize the benefits and harms of screening, and take into account patient values and preferences," Keating said.
The authors conclude that until new and better screening tests provide more benefit and fewer harms for patients, more efforts are needed to develop tools to support clinicians and patients in determining individual breast cancer risk and in making shared decisions about mammography.
In a supplement to the JAMA Insights article, the authors provide currently available resources to support shared decisions about breast cancer screening, including an animated video available here.
Source: Eurekalert
E-nose, Urine Tests Detect Early Breast Cancer
A new method for early and accurate breast cancer screening has been developed by researchers at Ben-Gurion University of the Negev and Soroka University Medical Center, using commercially available technology.
Advertisement
 Here's Why Breast Cancer Risk Increases in Older WomenChanges in breast tissue can increase the risk of developing breast cancer in older women, which helps us better understand how breast cells change during the aging process. | Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
The combination of the personalized cancer vaccine with ACT led to ovarian cancer control in few patients within a span of three months, stated study results.
Uncovering key kinases in tumor growth and invasion is crucial for improving targeted therapies in advanced-stage colorectal cancer.
The study findings validate metal-enhanced photo-oxidation for future metal-based anticancer drugs.
Mutations in 11 genes are linked to aggressive forms of prostate cancer, which may present novel therapeutic and therapy options.
Improved oral health, as indicated by the count of natural teeth and dental appointments preceding the diagnosis, correlated with enhanced head and neck cancer survival rates.
